Whole-body senescent cell clearance alleviates age-related brain inflammation and cognitive impairment in mice.

Ogrodnik M, Evans SA, Fielder E, Victorelli S, Kruger P, Salmonowicz H, Weigand BM, Patel AD, Pirtskhalava T, Inman CL, Johnson KO, Dickinson SL, Rocha A, Schafer MJ, Zhu Y, Allison DB, von Zglinicki T, LeBrasseur NK, Tchkonia T, Neretti N, Passos JF, Kirkland JL, Jurk D. · 2021

Read Whole-body senescent cell clearance alleviates age-related brain inflammation and cognitive impairment in mice. by Ogrodnik M, Evans SA, Fielder E, Victorelli S, Kruger P, Salmonowicz H, Weigand BM, Patel AD, Pirtskhalava T, Inman CL, Johnson KO, Dickinson SL, Rocha A, Schafer MJ, Zhu Y, Allison DB, von Zglinicki T, LeBrasseur NK, Tchkonia T, Neretti N, Passos JF, Kirkland JL, Jurk D. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7884042.txt.

Introduction

Ogrodnik and co-authors report a mouse study on clearing senescent cells from the ageing brain. Senescent cells have stopped dividing but stay active, releasing inflammatory signals. Their build-up is tied to ageing and age-related disease. The team asked whether removing them protects thinking skills.

The researchers first mapped senescent cells in the hippocampus of young and aged mice. Such cells rose with age, most of all in microglia. They then cleared the cells in two ways: with a drug switch in engineered mice, and with a senolytic drug pair. Both routes cut microglial activation and inflammatory signals. Both also improved cognitive function in the aged mice. The authors present the work as proof of concept for senolytic treatment of age-linked decline.

Catalog record

CREATOROgrodnik M, Evans SA, Fielder E, Victorelli S, Kruger P, Salmonowicz H, Weigand BM, Patel AD, Pirtskhalava T, Inman CL, Johnson KO, Dickinson SL, Rocha A, Schafer MJ, Zhu Y, Allison DB, von Zglinicki T, LeBrasseur NK, Tchkonia T, Neretti N, Passos JF, Kirkland JL, Jurk D.
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE74 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7884042

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Whole‐body senescent cell clearance alleviates age‐related brain inflammation and cognitive impairment in mice By Mikolaj Ogrodnik, Shane A Evans, Edward Fielder, Stella Victorelli, Patrick Kruger, Hanna Salmonowicz, Bettina M Weigand, Ayush D Patel, Tamar Pirtskhalava, Christine L Inman, Kurt O Johnson, Stephanie L Dickinson Published in: Aging Cell DOI: 10.1111/acel.13296 ABSTRACT Abstract Cellular senescence is characterized by an irreversible cell cycle arrest and a pro‐inflammatory senescence‐associated secretory phenotype (SASP), which is a major contributor to aging and age‐related diseases. Clearance of senescent cells has been shown to improve brain function in mouse models of neurodegenerative diseases. However, it is still unknown whether senescent cell clearance alleviates cognitive dysfunction during the aging process. To investigate this, we first conducted single‐nuclei and single‐cell RNA‐seq in the hippocampus from young and aged mice. We observed an age‐dependent increase in p16Ink4a senescent cells, which was more pronounced in microglia and oligodendrocyte progenitor cells and characterized by a SASP. We then aged INK‐ATTAC mice, in which p16Ink4a‐positive senescent cells can be genetically eliminated upon treatment with the drug AP20187 and treated them either with AP20187 or with the senolytic cocktail Dasatinib and Quercetin. We observed that both strategies resulted in a decrease in p16Ink4a exclusively in the microglial population, resulting in reduced microglial activation and reduced expression of SASP factors. Importantly, both approaches significantly improved cognitive function in aged mice. Our data provide proof‐of‐concept for senolytic interventions' being a potential therapeutic avenue for alleviating age‐associated cognitive impairment. Keywords: aging, brain, cognition, memory, neurodegeneration, SASP, senescence, senolytic, telomeres INTRODUCTION The aging process is characterized by a progressive decline in memory, attentional control, orientation, and cognition (Camandola & Mattson, 2017; Hof & Morrison, 2004). Furthermore, aging is a major risk factor for development of several neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS), primary progressive multiple sclerosis (PPMS), Alzheimer's disease (AD), and Parkinson's disease (PD) (Hou et al., 2019). Cellular senescence is a process characterized by an irreversible cell cycle arrest that can be induced by a variety of stresses, including oxidative stress, mitochondrial dysfunction, and telomere dysfunction, among others (Baker et al., 2016; Correia‐Melo et al., 2016; Hewitt et al., 2012; Ogrodnik et al., 2019). Senescent cells have been shown to accumulate in a variety of tissues with aging and at the etiological sites of chronic diseases (McHugh & Gil, 2018). Senescent cells are thought to exert their detrimental effects with aging and in age‐related diseases partially via the senescence‐associated secretory phenotype (SASP) (Coppé et al., 2008), which involves increased secretion of a number of pro‐inflammatory cytokines, chemokines, growth factors, and extracellular matrix proteases. The SASP can have beneficial effects, such as orchestrating the clearance of senescent cells (Ovadya et al., 2018; Xue et al., 2007). However, chronic exposure to the SASP is thought to contribute to the spreading of senescence to otherwise healthy tissues (Acosta et al., 2013; Nelson et al., 2012; Xu et al., 2018). Senescent cells have been shown to accumulate in the brain with aging. Senescent cell markers have been found in various brain cell types such as neurons, astrocytes, oligodendrocyte progenitor cells, microglia, ependymal cells, and endothelial cells (Bussian et al., 2018; Chinta et al., 2018; Jurk et al., 2012; Musi et al., 2018; Ogrodnik et al., 2018; Zhang et al., 2019). Furthermore, recent studies have shown that clearance of senescent cells had beneficial effects in mouse models of AD and tau‐dependent neurodegenerative diseases (Bussian et al., 2018; Musi et al., 2018; Zhang et al., 2019), PD (Chinta et al., 2018), PPMS (Nicaise et al., 2019), and ALS (Trias et al., 2019). However, currently it is not known if presence of senescent cells influences the progression of brain aging and age‐associated cognitive impairment. Here, we utilized the INK‐ATTAC transgenic mouse model, in which apoptosis of highly p16Ink4a‐expressing cells can be induced upon administration of the drug AP20187 (AP) (Baker et al., 2011). Of note, not every cell with high p16Ink4a expression is senescent and not every senescent cell has high levels of p16Ink4a expression. The second strategy we used is senolytic drug treatment with the combination of Dasatinib and Quercetin (D + Q), which were shown to clear senescent cells in vitro (Aguayo‐Mazzucato et al., 2019; Zhu et al., 2015), in vivo in peripheral organs (Aguayo‐Mazzucato et al., 2019; Ogrodnik et al., 2017; Xu et al., 2018; Zhu et al., 2015), and in the brain (Ogrodnik et al., 2018; Zhang et al., 2019). These drugs act by transiently disabling the Senescent Cell Anti‐apoptotic Pathways (SCAPs) that defend senescent cells from apoptosis; they do not act by killing cells based only on expression of p16Ink4a. The fundamental difference between both approaches is the fact that, in contrast to the INK‐ATTAC model which targets specifically highly p16Ink4a‐expressing cells, the D + Q senolytic cocktail does not target a specific molecule or biochemical pathway. Indeed, we have previously found that D targets tyrosine kinases, while flavonoid Q targets BCL‐2 family members as well as HIF‐1α and particular nodes in PI3‐kinase pathways (Zhu et al., 2015). Because different senescent cell types utilize diverse SCAPs to defend themselves against their own pro‐apoptotic microenvironment, we predict that strategies targeting multiple SCAPs will be more effective at removing senescent cells than drugs that have a single‐molecular target. We observed by single‐nucleus and single‐cell RNA‐seq that p16Ink4a positive cells increase in the hippocampus of aged mice in different cell populations; however, p16Ink4a is more abundant in microglia and oligodendrocyte progenitor cells. Intermittent, two‐month long treatment of aged INK‐ATTAC mice with AP or senolytics resulted in a significant attenuation of age‐associated cognitive dysfunction measured by the Stone T‐Maze. Moreover, we observed a reduction of p16Ink4a exclusively in the microglial population in the CA3 region of the hippocampus in both AP‐ and D + Q‐treated mice. Finally, we detected a mild but significant decrease in markers of inflammation, such as expression of pro‐inflammatory molecules, microglial activation, and infiltration of CD3‐positive T cells. Together, these data suggest that clearance of senescent cells is a viable therapeutic strategy to counteract age‐related cognitive decline. RESULTS Senescent cells accumulate in the brain during aging and exhibit changes in secretory phenotype 2.1. Previous data have indicated that cell senescence is a feature of brain pathology and aging (Bussian et al., 2018; Chinta et al., 2018; Fielder et al., 2020; Jurk et al., 2012; Musi et al., 2018; Nicaise et al., 2019; Trias et al., 2019; Zhang et al., 2019). However, the identity of senescent cells in the brain remains elusive as majority of studies utilized semi‐quantitative techniques (which rely on tissue homogenization) or immunohistochemical techniques that do not offer a comprehensive analysis of senescence in different cell populations. For these reasons, in this study we used single‐cell RNA sequencing (sc‐RNA‐seq) and single‐nucleus RNA sequencing (sn‐RNA‐seq) to profile and compare the cellular composition and transcriptomes of 4 young (4 months) and 4 old (24 months) mouse hippocampi, a region that plays a key role in memory formation (Figure 1, Figure S1). The dissociation and processing of mammalian adult brain tissue is challenging due to its complexity and can result in reduced yield of certain cell types, such as neurons. To address this issue and to generate datasets consisting of a broad range of brain cell types, we

Read the complete text